Highest-materiality recent filing
Net sales $80.9M, up 6.9% YoY; Med Tech $39.9M (+13.2%) and Med Device $41.0M (+1.4%); GAAP loss per share $0.17 vs $0.26 a year ago.
Honroth, 55, joins as President, CEO and board member on Nov 2, 2026, succeeding Jim Clemmer, who departs the board that day and stays on as a consultant.
AngioDynamics reports FY2026 Q4 pro forma sales $86.6M (+8% YoY); Med Tech growth 16.7%
Q4 FY2026 pro forma net sales $86.6M (+8.0% YoY); Med Tech $41.8M (+16.7%), Med Device $44.8M (+1.1%).
AngioDynamics Q3 FY2026: Med Tech sales up 19%, raises full-year guidance
Net sales $78.4M (+8.9% pro forma); Med Tech $37.3M (+19%) driven by Auryon, thrombectomy, NanoKnife.
CEO James C. Clemmer to retire by Nov 30, 2026; retention awards for NEOs
Clemmer will step down as CEO upon successor appointment or Nov 30, 2026; may extend month-to-month; to serve as consultant for one year.
AngioDynamics Q2 beats; raises FY26 guidance; CEO Clemmer to retire; Med Tech growth +13%
Q2 net sales $79.4M (+8.8% YoY); Med Tech $35.7M (+13.0%); GAAP EPS -$0.15, adj. EPS $0.00.
AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance
Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.
AngioDynamics Reports Strong Q4 and Full Year FY2025 Results; Med Tech Revenue Up 22%
Q4 pro forma net sales $80.2M, up 12.7% YoY; Med Tech sales grew 22% to $35.8M.
AngioDynamics raises FY2025 guidance after Q3; Med Tech sales up 22% YoY
Pro forma Q3 net sales $72.0M (+9.2% YoY); Med Tech $31.3M (+22.2%) driven by Auryon, AngioVac, AlphaVac, NanoKnife.
AngioDynamics Q2 pro forma sales up 9.2% to $73.0M; raises FY25 EBITDA guidance to $1-3M
Pro forma net sales $73.0M (+9.2% YoY); Med Tech $31.5M (+25%) led by AngioVac (+50.7%), Auryon (+21.8%), AlphaVac (+33.3%), NanoKnife disposables (+23.1%).
AngioDynamics Q1 FY2025 net sales $67.5M (+1.1% pro forma); GAAP EPS -$0.31, adj. EPS -$0.11
Med Tech segment sales $28.0M (+8.7% YoY) driven by Auryon at $13.7M (+24.9%) and AlphaVac at $2.2M (+21.1%).
AngioDynamics pro forma Q3 FY2024 net loss $187.8M on $159.5M goodwill impairment
Pro forma net loss for Feb 29, 2024 quarter was $187.8M vs $13.7M a year ago; includes $159.5M goodwill impairment.
AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M
Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.
Reported net sales $75.2M; pro forma $66.0M (+8.0% YoY). GAAP net loss $190.4M ($4.73/sh) includes $159.5M goodwill impairment and $22.0M litigation settlement.
AngioDynamics settles patent litigation with BD; $7M upfront, $2.5M annual minimums
One-time payment of $7M to BD, with $3M due within 5 business days and remainder over 12 months.
AngioDynamics cuts FY24 revenue guidance to $320-325M; Q2 revenue $79.1M, Auryon sales up 12.9%
FY24 revenue guidance lowered to $320M-$325M from $328M-$333M; adjusted EPS loss widens to ($0.35)-($0.42) from ($0.28)-($0.34).
AngioDynamics Q2 Revenue $79.1M, Per-Share Loss $0.72; Restructuring Manufacturing; SVP Resigns
Net sales $79.1M (up 2.7% pro-forma); GAAP net loss $29.0M or $0.72 per share; adjusted loss $0.05 per share
AngioDynamics Q1 FY2024 revenue $78.7M, pro-forma +5.7%; adj. loss $(0.12)/share
Net sales $78.7M (ex-Dialysis/BioSentry +5.7% YoY); Med Tech +13.3% on Auryon +25.7%, NanoKnife +34.5%.
AngioDynamics Q4 net sales up 4.7% to $91.1M; GAAP loss $0.54/share
Med Tech segment grew 17.2% to $26.5M, driven by Auryon +22%, NanoKnife +28%, AlphaVac +87%.
AngioDynamics sells dialysis & biopsy product portfolio to Merit Medical for $100M cash
Closed June 8, 2023; proceeds used to repay ~$49.8M in debt under credit agreement, terminating it.
AngioDynamics sells dialysis product portfolio and BioSentry to Merit Medical for $100M cash
Deal includes DuraFlow, DuraMax, Evenmore, Schon XL, Trio-CT, Vaxel Plus catheters and BioSentry biopsy product.
AngioDynamics wins court ruling invalidating three Bard patents in Delaware litigation
District Court granted AngioDynamics' Renewed Judgment as a Matter of Law on June 1, 2023.
Q3 net sales $80.7M (+9.1% YoY); GAAP loss per share $0.24 vs $0.13 loss last year; adjusted loss per share $0.03.
Net sales $85.4M, up 9.1% YoY; Med Tech +29.7% to $24.5M, Med Device +2.6% to $60.9M.
AngioDynamics loses patent infringement jury verdict to Bard on port products
Jury verdict found AngioDynamics' implantable port products infringe certain Bard patents (Nov 22, 2022).
AngioDynamics Q1 sales up 5.9% to $81.5M, GAAP loss $0.33/sh, reaffirms FY2023 outlook
Net sales of $81.5M increased 5.9% YoY; GAAP net loss of $13.0M or $0.33 per share vs $0.18 loss a year ago.
AngioDynamics loses antitrust jury verdict against C.R. Bard in PICC market
Jury found Bard did not unlawfully restrain competition in U.S. PICC market following two-week trial in N.D.N.Y.
AngioDynamics Q4 sales $87M (+13% YoY), GAAP EPS -$0.16; FY23 rev guide $342-348M
Q4 net sales $87.0M (+13.2% YoY); Med Tech sales up 40% to $22.6M.
Net sales $74.0M (+3.9% YoY); Med Tech +28.6% driven by Auryon ($7.3M) and thrombectomy; Med Device -2.8%.
On October 2, 2026, the Board of Directors of the Company (the “ Board ”) appointed Eric Honroth to serve as President and Chief Executive Officer of the Company, effective as of November 2, 2026 (the “ Effective Date ”) and concurrently with Mr. Clemmer’s retirement.
Mr. Clemmer has served as a member of the Board since 2016 and his decision to retire was not the result of any disagreement between Mr. Clemmer and the Company on any matter relating to the Company’s operations, polices or practices.
As previously disclosed, James C. Clemmer has announced his intention to retire from his position as the President and Chief Executive Officer of the Company on the earlier of November 30, 2026 and appointment of a successor Chief Executive Officer.
In addition, Mr. Honroth was appointed as a director on the Company’s Board as of the Effective Date, conditioned upon his commencement of service as President and Chief Executive Officer and concurrently with Mr. Clemmer’s retirement from his position as a member of the Board.
James Clemmer resigned from his position as a Class II director on the Board and was immediately re-appointed as a Class I director
Jan Stern Reed as the new chair of the Nominating, Compliance and Corporate Governance Committee
the Board appointed Wesley Johnson as the new chair of the Audit Committee
On January 16, 2024, Dennis Meteny announced his intention to retire and resign from his position as a member of the Board of Directors (the “Board”) of AngioDynamics, Inc. (“AngioDynamics” or the “Company”) and as a member of the Compensation Committee and chair of the Audit Committee, effective January 31, 2024.
On December 29, 2023, David D. Helsel, Senior Vice President of Global Operations and R&D, notified the Company of his intention to leave the Company, effective January 12, 2024, in order to pursue other opportunities.
On July 19, 2023, the board of directors (the “Board”) of AngioDynamics, Inc. (“AngioDynamics”) approved an increase in the size of the Board to a total of nine directors and appointed Lorinda Burgess as a Class III director of AngioDynamics, effective immediately.
Max materiality 0.90 · Median 0.61 · Most common event earnings